Skip to content

AARD AARD EBITDA

EBITDA at other companies

Relmada Therapeutics, Inc. logo
Relmada Therapeutics, Inc.RLMD
-$26.46M-148%
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-$43.93M-28.8%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
-$4.09M+78.7%
Arvinas logo
ArvinasARVN
-$63.1M-188%
Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
-$3.24M+83.0%
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Revenue-
Operating income-$22.5M-115%
Net income-$21.6M-132%
EPS (diluted)-$0.99-39.4%

Balance sheet

See full
Cash & equivalents$62.4M+136%
Total debt$336.0K-53.7%
Total equity$87.0M-42.3%
Total assets$98.6M-37.2%

Cash flow

See full
Operating cash flow-$18.9M-65.7%
CapEx--100%
Free cash flow-$16.8M-117%

Valuation

See full
Market cap$124.35M-58.6%
Enterprise value$62.25M-77.4%

Returns & leverage

See full
Return on equity-58.8%
Debt / equity0.0×
Current ratio8.1×-17.8×

Where this comes from

Calculated from AARD’s reported figures.

$22.5Mebit+
$11.0KDepreciation Depletion & Amortization
=-$22.45M

The official record: AARD’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about AARD's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AARD's EBITDA?
AARD (AARD) reported EBITDA of -$22.45M in Q1 2026.
How has AARD's EBITDA changed year-over-year?
AARD's EBITDA decreased by 114.6% year-over-year, from -$10.47M to -$22.45M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.